Clicky

Biohaven Pharmaceutical Holding Company Ltd.(BHVN)

Description: Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.


Keywords: Cancer Biopharmaceutical Organic Compounds Chemical Compounds Neuroscience Neurodegenerative Diseases Glutamate Neurotransmitters N Methyl D Aspartic Acid Chemical Entity Riluzole

Home Page: www.biohavenpharma.com

BHVN Technical Analysis

215 Church Street
New Haven, CT 06510
United States
Phone: 203 404 0410


Officers

Name Title
Dr. Vladimir Coric M.D. Chairman & CEO
Mr. Matthew Buten Chief Financial Officer
Mr. George C. Clark VP & Chief Accounting Officer
Dr. Bruce D. Car DACVP, Ph.D. Chief Scientific Officer
Ms. Jennifer Porcelli VP of Investor Relations
Mr. Warren Volles Gen. Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S. Chief Compliance Officer
Ms. Kimberly Gentile Sr. VP of Clinical Operations
Mr. John Tilton Chief Commercial Officer of Rare Diseases
Mr. Chris Barrett Sr. VP of Commercial Strategy, Common Disease

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 10.2225
Price-to-Sales TTM: 0
IPO Date: 2022-09-23
Fiscal Year End: December
Full Time Employees: 0
Back to stocks